FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/01/2024
Voltar para busca
Dado oficial do USPTO
SPYBIOTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
02/01/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
18/08/2021
Data de registro
05/09/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/09/2023
Última transação
05/09/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
CLARK, ANDREW
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SPYBIOTECH LIMITED
Representantes
Ben Natter Haug Partners, LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalbiopharmaceutical and medicinal preparations and substances for the treatment of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; vaccines; vaccine preparations; all of the foregoing for exclusive use in the vaccine and viral based therapeutics field
Classe 42
Medical and pharmaceutical research services; biological research; development of pharmaceutical preparations and medicines; research and development relating to biologics and vaccines; providing medical and scientific research information in the field of pharmaceuticals and vaccines; scientific research in the nature of conducting clinical trials for others in the vaccine and viral based therapeutics field; scientific and medical research consulting services in the nature of clinical trial design for vaccines for others; providing a bioinformatics platform for use in manufacturing therapeutics in the nature of platform as a service (PAAS) featuring computer software for medical data analysis; scientific services relating to the discoverypreclinical and clinical development of vaccines and therapeutic products in the nature of development of pharmaceutical preparations and medicines; research and development of new products for others; development of pharmaceutical products for others; informationadvisory and consultancy services relating to the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/12/2023
FIMP
FINAL DISPOSITION PROCESSED
07/12/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/12/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/09/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
05/09/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/06/2023
PUBO
PUBLISHED FOR OPPOSITION
20/06/2023
GPNX
NOTIFICATION PROCESSED BY IB
19/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
31/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/05/2023
MNDA
NOTICE OF DIVIDED TRADEMARK APPLICATION MAILED
18/04/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
12/04/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/04/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/04/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/03/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
15/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/03/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
13/03/2023
DRRR
DIVISIONAL REQUEST RECEIVED
27/02/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
27/02/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/01/2023
GNFR
FINAL REFUSAL E-MAILED
13/01/2023
CNFR
FINAL REFUSAL WRITTEN
13/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/11/2022
RFNT
REFUSAL PROCESSED BY IB
19/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/06/2022
RFRR
REFUSAL PROCESSED BY MPU
28/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
15/06/2022
CNRT
NON-FINAL ACTION WRITTEN
14/06/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
13/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/06/2022
CNRT
NON-FINAL ACTION WRITTEN
06/06/2022
DOCK
ASSIGNED TO EXAMINER
20/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
19/10/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/10/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SPYBIOTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.